Thank you very much, Mr. Chair.
You mentioned in your last statement, Madam Rowden, that IPIC would like to see counterfeiting laws tightened up. I'm a little confused about your testimony today, because it seems to fly in the face of previous testimony. We just did a study on counterfeiting, and the preponderance of the evidence we heard was that Canada's laws aren't strong enough and we're not tough enough.
You also mentioned that VANOC would be treated differently in its ability to obtain interlocutory injunctions. I believe that's not the case. We also have other cases in which there's an exemption. VANOC's not the only entity to enjoy specialized access to interlocutory relief; the patented medicines regulations provide automatic 24-month stays to pharmaceutical patents seeking to prevent a suspected infringing generic competitor from entering the market.
I would like you to explain the difference in opinion. It seems that on the one hand IPIC wants us to tighten up on counterfeiting and give stronger laws, but here you're almost saying that we're going too far.
Could you explain the difference to the committee?